PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming-Sound Tsao,Keith M. Kerr,Mark M. Kockx,Mary Beth Beasley,Alain C. Borczuk,Johan Botling,Lukas Bubendorf,Lucian R. Chirieac,Gang Chen,Teh Ying Chou,Jin Haeng Chung,Sanja Dacic,Sylvie Lantuejoul,Mari Mino-Kenudson,Andre L. Moreira,Andrew G. Nicholson,Masayuki Noguchi,Giuseppe Pelosi,Claudia Poleri,Prudence A. Russell,Jennifer L. Sauter,Erik Thunnissen,Ignacio I. Wistuba,Hui Yu,Murry W. Wynes,Melania Pintilie,Yasushi Yatabe,Fred R. Hirsch +27 more
TLDR
The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L 1 immunohistochemical assays.About:
This article is published in Journal of Thoracic Oncology.The article was published on 2018-09-01 and is currently open access. It has received 550 citations till now.read more
Citations
More filters
Journal ArticleDOI
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde,Daniel S. Chen +1 more
TL;DR: Ten key challenges facing cancer immunotherapy are defined, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient.
Journal ArticleDOI
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
David S. Ettinger,David S. Ettinger,Douglas E. Wood,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Wallace Akerley,Jessica Bauman,Jessica Bauman,Ankit Bharat,Ankit Bharat,Debora S. Bruno,Debora S. Bruno,Joe Y. Chang,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Thomas J. Dilling,Jonathan E. Dowell,Scott N. Gettinger,Matthew A. Gubens,Aparna Hegde,Mark Hennon,Mark Hennon,Rudy P. Lackner,Michael Lanuti,Michael Lanuti,Ticiana A. Leal,Ticiana A. Leal,Jules Lin,Jules Lin,Billy W. Loo,Christine M. Lovly,Christine M. Lovly,Renato Martins,Renato Martins,Erminia Massarelli,Erminia Massarelli,Daniel Morgensztern,Daniel Morgensztern,Thomas Ng,Thomas Ng,Gregory A. Otterson,Gregory A. Otterson,Sandip P. Patel,Sandip P. Patel,Gregory J. Riely,Gregory J. Riely,Steven E. Schild,Steven E. Schild,Theresa A. Shapiro,Theresa A. Shapiro,Aditi P. Singh,Aditi P. Singh,James P. Stevenson,James P. Stevenson,Alda Tam,Alda Tam,Jane Yanagawa,Jane Yanagawa,Stephen C. Yang,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +64 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC as mentioned in this paper.
Journal ArticleDOI
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip,Nasser K. Altorki,Caicun Zhou,Tibor Csőszi,Ihor Vynnychenko,Oleksandr Goloborodko,Alexander Luft,Andrey Akopov,Alex Martinez-Marti,Hirotsugu Kenmotsu,Yuh-Min Chen,Antonio Chella,Shunichi Sugawara,David Voong,Fan Wu,Jing Yi,Yu Deng,Mark McCleland,Elizabeth Bennett,Barbara J. Gitlitz,Heather A. Wakelee,IMpower Investigators +21 more
TL;DR: The IMpower010 trial as mentioned in this paper evaluated adjuvant atezolizumab versus best supportive care (observation and regular scans for disease recurrence) in patients with early-stage non-small-cell lung cancer.
Journal ArticleDOI
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah B. Doroshow,Sheena Bhalla,Mary Beth Beasley,Lynette M. Sholl,Keith M. Kerr,Sacha Gnjatic,Ignacio I. Wistuba,David L. Rimm,Ming-Sound Tsao,Fred R. Hirsch +9 more
TL;DR: In this paper, the authors describe the current role of PD-L1 immunohistochemistry assays used to inform the selection of patients to receive antiPD-1 or anti-PD-L 1 antibodies, discuss the various technical and clinical challenges associated with these assays, including regulatory issues, and provide some perspective on how to optimize PDL1 as a selection biomarker for the future treatment of patients with solid tumours.
Journal ArticleDOI
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah Blythe Doroshow,Miguel F. Sanmamed,Katherine Hastings,Katerina Politi,David L. Rimm,Lieping Chen,Ignacio Melero,Kurt A. Schalper,Roy S. Herbst +8 more
TL;DR: The advances to date in utilizing PD-L1 and tumor mutational burden, as well as novel markers of tumor inflammation, to ascertain which patients are most likely to benefit from ICIs are described.
References
More filters
Journal ArticleDOI
Statistical methods for assessing agreement between two methods of clinical measurement.
TL;DR: An alternative approach, based on graphical techniques and simple calculations, is described, together with the relation between this analysis and the assessment of repeatability.
Journal ArticleDOI
A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research
Terry K. Koo,Mae Y. Li +1 more
TL;DR: A practical guideline for clinical researchers to choose the correct form of ICC is provided and the best practice of reporting ICC parameters in scientific publications is suggested.
Journal ArticleDOI
Statistical methods for assessing agreement between two methods of clinical measurement
TL;DR: In this article, an alternative approach, based on graphical techniques and simple calculations, is described, together with the relation between this analysis and the assessment of repeatability, which is often used in clinical comparison of a new measurement technique with an established one.
Journal ArticleDOI
Interrater reliability: the kappa statistic
TL;DR: While the kappa is one of the most commonly used statistics to test interrater reliability, it has limitations and levels for both kappa and percent agreement that should be demanded in healthcare studies are suggested.
Journal ArticleDOI
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch,Abigail McElhinny,Dave Stanforth,James Ranger-Moore,Malinka Jansson,Karina Kulangara,William Richardson,Penny Towne,Debra Hanks,Bharathi Vennapusa,Amita Mistry,Rasika Kalamegham,Rasika Kalamegham,Steve Averbuch,James Novotny,Eric J. Rubin,Kenneth Emancipator,Ian McCaffery,J. Andrew Williams,Jill Walker,John W. Longshore,Ming-Sound Tsao,Keith M. Kerr +22 more
TL;DR: The Blueprint PD‐L1 IHC Assay Comparison Project revealed that three of the four assays were closely aligned on tumor cell staining whereas the fourth showed consistently fewer tumor cells stained, indicating that interchanging assays and cutoffs would lead to “misclassification” of PD‐ L1 status for some patients.
Related Papers (5)
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more